48.17 USD
+0.66 (+1.39%)
47.89 USD
-0.28 (-0.58%)
SNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
SNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SNY (11.05%) is better than 92.15% of its industry peers.
SNY has a Return On Equity of 19.73%. This is amongst the best in the industry. SNY outperforms 90.05% of its industry peers.
SNY has a Return On Invested Capital of 13.84%. This is amongst the best in the industry. SNY outperforms 93.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 12.85%.
The last Return On Invested Capital (13.84%) for SNY is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY has a Profit Margin of 20.35%. This is amongst the best in the industry. SNY outperforms 91.10% of its industry peers.
In the last couple of years the Profit Margin of SNY has grown nicely.
Looking at the Operating Margin, with a value of 23.59%, SNY belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
SNY's Gross Margin of 71.70% is fine compared to the rest of the industry. SNY outperforms 78.53% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SNY is creating value.
Compared to 1 year ago, SNY has about the same amount of shares outstanding.
SNY has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
SNY's Debt to FCF ratio of 2.21 is amongst the best of the industry. SNY outperforms 93.19% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SNY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.21, SNY perfoms like the industry average, outperforming 44.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.35%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.27, SNY is doing worse than 78.01% of the companies in the same industry.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.94, SNY is not doing good in the industry: 79.06% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.35%.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
The Revenue has been growing slightly by 2.56% in the past year.
Measured over the past years, SNY shows a small growth in Revenue. The Revenue has been growing by 3.31% on average per year.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 7.11% on average per year.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 4.55% on average per year.
EPS Next Y2.37%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
EPS Next 5Y7.11%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.55%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.75, which indicates a very decent valuation of SNY.
SNY's Price/Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 90.58% of the companies in the same industry.
SNY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.17.
Based on the Price/Forward Earnings ratio of 9.61, the valuation of SNY can be described as reasonable.
SNY's Price/Forward Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 88.48% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (23.79), we can say SNY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.75 | ||
| Fwd PE | 9.61 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaper than 97.38% of the companies in the same industry.
92.15% of the companies in the same industry are more expensive than SNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.89 | ||
| EV/EBITDA | 5.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.54
PEG (5Y)2.11
EPS Next 2Y5.23%
EPS Next 3Y5.91%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.68%, SNY has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 0.42, SNY pays a better dividend. On top of this SNY pays more dividend than 94.24% of the companies listed in the same industry.
SNY's Dividend Yield is a higher than the S&P500 average which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.68% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
34.82% of the earnings are spent on dividend by SNY. This is a low number and sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
48.17
+0.66 (+1.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.74%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap117.00B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target62.25 (29.23%)
Short Float %0.35%
Short Ratio3.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.68% |
Yearly Dividend2.23
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-1.46%
PT rev (3m)-2.37%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-4.26%
EPS NY rev (1m)-0.63%
EPS NY rev (3m)-2.01%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.49%
Revenue NY rev (1m)-0.72%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.75 | ||
| Fwd PE | 9.61 | ||
| P/S | 1.47 | ||
| P/FCF | 9.89 | ||
| P/OCF | 8.75 | ||
| P/B | 1.42 | ||
| P/tB | 10.71 | ||
| EV/EBITDA | 5.43 |
EPS(TTM)4.48
EY9.3%
EPS(NY)5.01
Fwd EY10.4%
FCF(TTM)4.87
FCFY10.11%
OCF(TTM)5.5
OCFY11.43%
SpS32.84
BVpS33.87
TBVpS4.5
PEG (NY)4.54
PEG (5Y)2.11
Graham Number58.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.35%
ROIC/WACC1.88
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y2.37%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
EPS Next 5Y7.11%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.55%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.1%
EBIT Next 3Y13.19%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
Can you provide the valuation status for SANOFI-ADR?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What are the PE and PB ratios of SANOFI-ADR (SNY) stock?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.75 and the Price/Book (PB) ratio is 1.42.
How sustainable is the dividend of SANOFI-ADR (SNY) stock?
The dividend rating of SANOFI-ADR (SNY) is 6 / 10 and the dividend payout ratio is 34.82%.